News and Press Releases

WCG Expands New Statistical Consulting Solutions to Address Industry Resource Challenges

4 March 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the...

Category: Clinical Trials
Posted: March 4, 2024

212 Carnegie Center, Suite 301, Princeton, NJ 08540, USA

Janssen Receives Positive CHMP Opinion for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma

Results from the phase 3 CARTITUDE-4 study, which supported the CHMP recommendation, showed that cilta-cel has the potential to offer significant benefit to patients in earlier lines of treatment Most...

Category: Clinical Trials
Posted: February 23, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Aotearoa Clinical Trials Becomes First Site in New Zealand to Achieve both GCSA Certification and Silver Workforce Quality Accreditation

Certifications demonstrate Aotearoa Clinical Trials is working to the highest global best-practice standards, ratified by the industry 21 February 2024 -- Auckland, New Zealand and Maidenhead, UK -- Aotearoa Clinical Trials...

Category: Clinical Trials
Posted: February 21, 2024

Esme Green Building Middlemore Hospital 100 Hospital Rd Papatoetoe, 2025 Auckland, New Zealand

Principal IRB Becomes Univo IRB With Support From QHP Capital

20 February 2024 -- North Carolina -- Today, Univo IRB was announced as the new company name for Principal IRB. Univo IRB is a next generation institutional review board (IRB) recently acquired...

Category: Clinical Trials
Posted: February 20, 2024

4509 Creedmoor Road, Suite 403 Raleigh, NC 27612

Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT (amivantamab), in combination with Lazertinib, for the First-Line Treatment of Patients with EGFR Mutated Non-Small Cell Lung Cancer

The submission is supported by data from the Phase 3 MARIPOSA study, showing statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated with...

Category: Drug Discovery
Posted: February 8, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial

Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...

Category: Drug Discovery
Posted: February 7, 2024

C/ Natzaret, 115-117 Barcelona, Spain, 08035

Greenphire Announces Acquisition of Clincierge to Enhance Clinical Trial Support Services

Addition enables sponsors to solve the number one clinical trial participant obstacle – transportation, with a single industry-leading solution 1 February 2024 -- Pennsylvania, US -- Greenphire, a leading innovator in...

Category: Clinical Trials
Posted: February 1, 2024

1018 W. 9th Avenue, Suite 200 King of Prussia, PA 19406

Almost half of Brits think the Government is doing too little to encourage development of new medicines in the UK 

25 January -- London, UK -- Recent YouGov polling commissioned by clinical trials start-up Lindus Health has found that 47% of Brits want the Government to be doing more to...

Category: Pharmaceutical
Posted: January 25, 2024

unit 1, 120 Weston St, London SE1 4XE

Phesi releases 2023 analysis of clinical development; breast cancer remains most studied disease area for third year

Annual analysis of data from 95 million patients shows signs of post-pandemic recovery for clinical development industry, but trial cancellation rates at phase 2 remain high 16 January 2024 --...

Category: Clinical Trials
Posted: January 16, 2024

East Lyme, Connecticut, US

AiCuris Received €15m Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients

PREVYMIS now approved in the US and Europe for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]) EMA approval...

Category: Pharmaceutical
Posted: January 9, 2024

Friedrich-Ebert-Str. 475 / Building 302 42117 Wuppertal Germany

Headlands Research Announces Partnership with Sahara Behavioral Health

The collaboration improves access to clinical research and investigational treatments while supporting participant recruitment efforts in Arizona 4 January 2024 -- California, US -- Headlands Research, a leading multinational network...

Category: Clinical Trials
Posted: January 5, 2024

130 John F Kennedy Dr STE 203 Lake Worth, FL 33462

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

5 January 2024 -- Helsinki, Finland -- Nanoform Finland, the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate...

Category: Clinical Trials
Posted: January 5, 2024

Cultivator II, Viikinkaari 4 FI-00790 Helsinki, Finland

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer

The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO CongressLazertinib is a highly selective, central...

Category: Clinical Trials
Posted: December 21, 2023

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Lindus Health and Thirty Madison complete enrolment of personalised dermatology care pilot study

14 December 2023 -- London, UK -- Clinical trial company Lindus Health and Thirty Madison, a US-based family of specialised healthcare brands, have today announced the completion of enrolment of...

Category: Clinical Trials
Posted: December 14, 2023

unit 1, 120 Weston St, London SE1 4XE

PlaqueTec recruits first ten patients in BIOPATTERN trial

Trial to investigate atherosclerotic cardiovascular diseases receives MHRA approval to continue recruitment towards 300-patient target Unique PlaqueTec Liquid Biopsy System will be used to collect blood samples containing biomolecules localising...

Category: Clinical Trials
Posted: November 29, 2023

Maia Building (B270) Babraham Research Campus Cambridge CB22 3AT